DOI QR코드

DOI QR Code

Estrogen Receptor α Roles in Breast Cancer Chemoresistance

  • Xu, Chao-Yang (Department of Breast and Thyroid Surgery, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University) ;
  • Jiang, Zhi-Nong (Department of Pathology, Sir Run Run Shaw Hospital, Zhejiang University College of Medicine) ;
  • Zhou, Ying (Department of Breast and Thyroid Surgery, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University) ;
  • Li, Jia-Jia (Department of Breast and Thyroid Surgery, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University) ;
  • Huang, Li-Ming (Department of Breast and Thyroid Surgery, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University)
  • Published : 2013.07.30

Abstract

Resistance to chemotherapy treatment, which may lead to limited efficacy of systemic therapy in breast cancer patients, is multifactorial. Among the mechanisms of resistance to chemotherapy treatment, there are those closely related to estrogen receptor ${\alpha}$, P-glycoprotein, multidrug resistance-related protein, glutathione S-transferase pi and topoisomerase-II. $ER{\alpha}$ is ligand-activated transcription factor that regulates gene expression and plays a critical role in endocrine signaling. In previous preclinical and clinical studies, positive $ER{\alpha}$ expression in breast cancer cells was correlated with decreased sensitivity to chemotherapy. This article reviews current knowledge on the predictive value of $ER{\alpha}$ with regard to response to chemotherapy. Better understanding of its role may facilitate patient selection of therapeutic regimens and lead to optimal clinical outcomes.

Keywords

Estrogen receptor ${\alpha}$;chemoresistance;breast cancer;Fulvestrant

References

  1. Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, et al (2012). Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors, a GINECO study. J Clin Oncol, 30, 2718-24. https://doi.org/10.1200/JCO.2011.39.0708
  2. Bailey ST, Shin H, Westerling T, et al (2012). Estrogen receptor prevents p53-dependent apoptosis in breast cancer. Proc Natl Acad Sci U S A, 109, 18060-5. https://doi.org/10.1073/pnas.1018858109
  3. Bailey ST, Shin H, Westerling T, et al (2012). Estrogen receptor prevents p53-dependent apoptosis in breast cancer. Proc Natl Acad Sci U S A, 109, 18060-5. https://doi.org/10.1073/pnas.1018858109
  4. Chen D, Hackl W, Ortmann O, et al (2004). Effects of a combination of exemestane and paclitaxel on human tumor cells in vitro. Anticancer Drugs, 15, 55-61. https://doi.org/10.1097/00001813-200401000-00009
  5. Cohen I (2008). Aromatase inhibitors and the endometrium. Maturitas, 59, 285-92. https://doi.org/10.1016/j.maturitas.2008.03.001
  6. Coleman RE, Body JJ, Gralow JR, et al (2008). Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies. Cancer Treat Rev, 34, S31-42. https://doi.org/10.1016/j.ctrv.2008.03.005
  7. Donmez Y, Akhmetova L, Iseri OD, Kars MD, Gunduz U (2011). Effect of MDR modulators verapamil and promethazine on gene expression levels of MDR1 and MRP1 in doxorubicinresistant MCF-7 cells. Cancer Chemother Pharmacol, 67, 823-8. https://doi.org/10.1007/s00280-010-1385-y
  8. Dziadyk JM, Sui M, Zhu X (2004). Paclitaxel-induced apoptosis may occur without a prior G2/M-phase arrest. Anticancer Res, 24, 27-36.
  9. Early Breast Cancer Trialists Collaborative Group (EBCTCG), Clarke M, Coates AS, et al (2008). Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer, patient-level metaanalysis of randomised trials. Lancet, 371, 29-40. https://doi.org/10.1016/S0140-6736(08)60069-0
  10. Fisher B, Dignam J, Bryant J, et al (1996). Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst, 88, 1529-42. https://doi.org/10.1093/jnci/88.21.1529
  11. Fleeman N, Martin Saborido C, Payne K, et al (2011). The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen, a systematic review. Health Technol Assess, 15, 1-102.
  12. Geisler J, Smith I, Miller W (2012). Presurgical (neoadjuvant) endocrine therapy is a useful model to predict response and outcome to endocrine treatment in breast cancer patients. J Steroid Biochem Mol Biol, 131, 93-100. https://doi.org/10.1016/j.jsbmb.2011.12.006
  13. Gilani RA, Kazi AA, Shah P, et al (2012). The importance of HER2 signaling in the tumor-initiating cell population in aromatase inhibitor-resistant breast cancer. Breast Cancer Res Treat, 135, 681-92. https://doi.org/10.1007/s10549-012-2148-8
  14. Goncalves R, Ma C, Luo J, et al (2012). Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancer. Nat Rev Clin Oncol, 9, 223-9. https://doi.org/10.1038/nrclinonc.2012.21
  15. Jeong JH, Jung SY, Park IH, et al (2012). Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer. Invest New Drugs, 30, 408-16. https://doi.org/10.1007/s10637-010-9555-7
  16. Jiang Z, Guo J, Shen J, et al (2012). The role of estrogen receptor alpha in mediating chemoresistance in breast cancer cells. J Exp Clin Cancer Res, 31, 42. https://doi.org/10.1186/1756-9966-31-42
  17. Karroum A, Mirshahi P, Faussat AM, et al (2012). Tubular network formation by adriamycin-resistant MCF-7 breast cancer cells is closely linked to MMP-9 and VEGFR-2/VEGFR-3 over-expressions. Eur J Pharmacol, 685, 1-7. https://doi.org/10.1016/j.ejphar.2012.04.004
  18. Kemp Z, Jones A (2011). A shift in the treatment of hormone receptor and human epidermal growth factor receptor 2-positive metastatic breast cancer. Adv Ther, 28, 603-14. https://doi.org/10.1007/s12325-011-0050-0
  19. Larsen MS, Bjerre K, Giobbie-Hurder A, et al (2012). Prognostic value of Bcl-2 in two independent populations of estrogen receptor positive breast cancer patients treated with adjuvant endocrine therapy. Acta Onco, 51, 781-9. https://doi.org/10.3109/0284186X.2011.653009
  20. Lips EH, Mulder L, de Ronde JJ, et al (2012). Neoadjuvant chemotherapy in ER+ HER2- breast cancer, response prediction based on immunohistochemical and molecular characteristics. Breast Cancer Res Treat, 131, 827-36. https://doi.org/10.1007/s10549-011-1488-0
  21. Lv M, Li B, Li Y, et al (2011). Predictive role of molecular subtypes in response to neoadjuvant chemotherapy in breast cancer patients in Northeast China. Asian Pac J Cancer Prev, 12, 2411-7.
  22. Mutoh K, Tsukahara S, Mitsuhashi J, et al (2006). Estrogen-mediated post transcriptional down-regulation of P-glycoprotein in MDR1-transduced human breast cancer cells. Cancer Sci, 97, 1198-204. https://doi.org/10.1111/j.1349-7006.2006.00300.x
  23. Natarajan K, Xie Y, Baer MR, et al (2012). Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. Biochem Pharmacol, 83, 1084-103. https://doi.org/10.1016/j.bcp.2012.01.002
  24. Oliveira CA, Nie R, Carnes K, et al (2003). The antiestrogen ICI 182,780 decreases the expression of estrogen receptor-alpha but has no effect on estrogen receptor-beta and androgen receptor in rat efferent ductules. Reprod Biol Endocrinol, 1, 75. https://doi.org/10.1186/1477-7827-1-75
  25. Osako T, Nishimura R, Okumura Y, et al (2012). Predictive significance of the proportion of ER-positive or PgR-positive tumor cells in response to neoadjuvant chemotherapy for operable HER2-negative breast cancer. Exp Ther Med, 3, 66-71.
  26. Petit T, Wilt M, Velten M, et al (2010). Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer. Breast Cancer Res Treat, 124, 387-91. https://doi.org/10.1007/s10549-010-1142-2
  27. Precht LM, Lowe KA, Atwood M, et al (2010). Neoadjuvant chemotherapy of breast cancer, tumor markers as predictors of pathologic response, recurrence, and survival. Breast J, 16, 362-8.
  28. Puhalla S, Bhattacharya S, Davidson NE (2012). Hormonal therapy in breast cancer, a model disease for the personalization of cancer care. Mol Oncol, 6, 222-36. https://doi.org/10.1016/j.molonc.2012.02.003
  29. Romero A, Mart n M, Cheang MC, et al (2011). Assessment of Topoisomerase II ${\alpha}$ status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization. Am J Pathol, 178, 1453-60. https://doi.org/10.1016/j.ajpath.2010.12.042
  30. Romero A, Mart n M, Oliva B, et al (2012). Glutathione S-transferase P1 c.313A > G polymorphism could be useful in the prediction of doxorubicin response in breast cancer patients. Ann Oncol, 23, 1750-6. https://doi.org/10.1093/annonc/mdr483
  31. Saylam B, Efesoy O, Cayan S (2011). The effect of aromatase inhibitor letrozole on body mass index, serum hormones, and sperm parameters in infertile men. Fertil Steril, 95, 809-11. https://doi.org/10.1016/j.fertnstert.2010.09.021
  32. Shi R, Li W, Zhang X, et al (2011). A novel indirubin derivative PHII-7 potentiates adriamycin cytotoxicity via inhibiting P-glycoprotein expression in human breast cancer MCF-7/ADR cells. Eur J Pharmacol, 669, 38-44. https://doi.org/10.1016/j.ejphar.2011.07.047
  33. Sui M, Huang Y, Park BH, et al (2007). Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death. Cancer Res, 67, 5337-44. https://doi.org/10.1158/0008-5472.CAN-06-4582
  34. Tabuchi Y, Matsuoka J, Gunduz M, et al (2009). Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer. Int J Oncol, 34, 313-9.
  35. Tokuda E, Seino Y, Arakawa A, et al (2012). Estrogen receptor-_directly regulates sensitivity to paclitaxel in neoadjuvant chemotherapy for breast cancer. Breast Cancer Res Treat, 133, 427-36. https://doi.org/10.1007/s10549-011-1758-x
  36. Walker CH, Drew BA, Antoon JW (2012). Neurocognitive effects of chemotherapy and endocrine therapies in the treatment of breast cancer, recent perspectives. Cancer Invest, 30, 135-48. https://doi.org/10.3109/07357907.2011.636116
  37. Wang L, Jiang Z, Sui M, et al (2009). The potential biomarkers in predicting pathologic response of breast cancer to three different chemotherapy regimens, a case control study. BMC Cancer, 9, 226. https://doi.org/10.1186/1471-2407-9-226
  38. Wu L and Tannock IF (2005). Effect of the selective estrogen receptor modulator arzoxifene on repopulation of hormone-responsive breast cancer xenografts between courses of chemotherapy. Clin Cancer Res, 11, 8195-200. https://doi.org/10.1158/1078-0432.CCR-05-1258
  39. Xu C, Li J, Lu Y, et al (2012). Estrogen receptor ${\alpha}$ and hedgehog signal pathway developmental biology of gastric adenocarcinoma. Hepatogastroenterology, 59, 1319-22.

Cited by

  1. Over-Expression of Beclin-1 Facilitates Acquired Resistance to Histone Deacetylase Inhibitor-Induced Apoptosis vol.15, pp.18, 2014, https://doi.org/10.7314/APJCP.2014.15.18.7913
  2. In Silico Docking Studies of Selected Flavonoids - Natural Healing Agents against Breast Cancer vol.15, pp.19, 2014, https://doi.org/10.7314/APJCP.2014.15.19.8155
  3. Multivariate Analysis of Prognostic Factors in Male Breast Cancer in Serbia vol.15, pp.7, 2014, https://doi.org/10.7314/APJCP.2014.15.7.3233
  4. Identifying Differentially Expressed Genes and Screening Small Molecule Drugs for Lapatinib-resistance of Breast Cancer by a Bioinformatics Strategy vol.15, pp.24, 2015, https://doi.org/10.7314/APJCP.2014.15.24.10847
  5. Sequence to Structure Approach of Estrogen Receptor Alpha and Ligand Interactions vol.16, pp.6, 2015, https://doi.org/10.7314/APJCP.2015.16.6.2161
  6. Types of Cancers Prevailing in Pakistan and their Management Evaluation vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.3605
  7. Correlation of BCL-2 and ERα mRNA Expression with the Clinical Chemotherapeutic Response in Breast Cancer vol.17, pp.1, 2017, https://doi.org/10.3923/jms.2017.31.37
  8. Estrogen receptor-alpha gene XbaI A > G polymorphism influences short-term cognitive decline in healthy oldest-old individuals vol.75, pp.3, 2017, https://doi.org/10.1590/0004-282x20170018
  9. Genome-wide study of ER-regulated lncRNAs shows AP000439.3 may function as a key regulator of cell cycle in breast cancer vol.38, pp.5, 2017, https://doi.org/10.3892/or.2017.5975
  10. miR-191/DAB2 axis regulates the tumorigenicity of estrogen receptor-positive breast cancer vol.70, pp.1, 2017, https://doi.org/10.1002/iub.1705